Leukaemia treatment aims to control symptoms, eliminate cancer cells, and help patients live longer, healthier lives. The approach depends on the type of leukaemia, the patient’s age, overall health, and how far the disease has progressed. While standard treatments have been used successfully for years, new therapies tested in clinical trials are offering fresh hope for better outcomes.

Understanding Treatment Goals and Approaches

When someone receives a leukaemia diagnosis, the immediate focus shifts to finding the right treatment path. The main goals of treatment are to destroy the abnormal blood cells that are multiplying in the bone marrow, restore normal blood cell production, manage symptoms, and prevent the disease from spreading to other parts of the body. For some patients, treatment aims to achieve complete remission, which means no leukaemia cells can be detected in the body. For others, especially those with chronic forms of the disease, the goal may be to control the condition and maintain quality of life over many years.^[1][2]

Treatment decisions are never made in isolation. Healthcare teams consider multiple factors before recommending a specific approach. These factors include which type of leukaemia the patient has, whether it’s acute (fast-growing) or chronic (slow-growing), the patient’s age and general health, any other medical conditions they might have, and how the patient responds to initial treatments. Younger patients might be able to tolerate more intensive treatments than older adults, and those with additional health problems may need gentler approaches.^[3][6]

Medical societies and expert panels have developed guidelines that help doctors choose the most appropriate treatments based on years of research and clinical experience. These guidelines are regularly updated as new evidence becomes available. At the same time, researchers around the world are continuously testing new drugs and treatment methods in clinical trials, searching for ways to improve outcomes and reduce side effects.^[4][10]

Standard Treatment Methods

Chemotherapy remains the cornerstone of leukaemia treatment for many patients. This approach uses powerful medicines to kill cancer cells or stop them from growing and dividing. For acute leukaemias, which grow quickly and need immediate attention, chemotherapy is typically given in two main phases. The first phase, called induction, aims to kill as many leukaemia cells as possible in the blood and bone marrow. The goal is to bring the disease into remission. The second phase, consolidation, works to destroy any remaining cancer cells and prevent the disease from coming back.^[14][15]

During intensive induction chemotherapy, patients usually receive a combination of two or more chemotherapy drugs. These medicines are typically given through a thin tube inserted into a vein near the heart or in the arm. Because this treatment is very intensive, patients need to stay in hospital or visit a specialist centre where they can be closely monitored. The treatment affects not just cancer cells but also healthy blood cells, so patients need regular blood transfusions to replace missing red blood cells, white blood cells, and platelets. They’re also at high risk of infection, so antibiotics are often prescribed as a protective measure.^[14]

For chronic leukaemias, which develop more slowly, the treatment approach is often different. Some patients may not need immediate treatment at all. Instead, doctors might recommend a strategy called watchful waiting, where the patient is carefully monitored with regular check-ups and blood tests, and treatment only starts when the disease begins to progress or cause symptoms. When treatment is needed for chronic leukaemia, it often involves less intensive chemotherapy or targeted drugs that can be taken as tablets or given through injections under the skin, sometimes on an outpatient basis.^[3][10]

Targeted therapy represents a more refined approach that has emerged over recent years. These treatments work by attacking specific features of leukaemia cells, causing less damage to normal cells compared to traditional chemotherapy. For example, patients with chronic myeloid leukaemia often receive drugs that target a specific abnormal protein produced by cancer cells. One well-known medicine is imatinib, which blocks signals that tell leukaemia cells to grow. Other targeted drugs work in similar ways but may be used when the first treatment stops working or causes too many side effects.^[3][15]

Radiation therapy uses high-energy beams to kill cancer cells. In leukaemia treatment, radiation is not used as commonly as chemotherapy, but it plays an important role in specific situations. It may be used when leukaemia has spread to the brain or nervous system, or to prepare the body for a stem cell transplant by destroying cancer cells in the bone marrow. Some patients receive radiation to specific areas where leukaemia cells have built up, such as the spleen or lymph nodes. Side effects of radiation therapy can include hair loss in the treated area, nausea, and fatigue, though most side effects fade after treatment ends.^[14][15]

For certain types of acute leukaemia, particularly acute promyelocytic leukaemia, doctors prescribe additional medicines alongside chemotherapy. All-trans retinoic acid, or ATRA, is one such medicine that changes immature white blood cells into healthy, mature cells. It can quickly reduce symptoms and is usually given during and after induction chemotherapy. Another medicine, arsenic trioxide, speeds up the death of leukaemia cells and may be used if the cancer returns. ATRA can cause side effects including headaches, nausea, bone pain, dry mouth, and dry skin or eyes.^[14]

A stem cell transplant, also called a bone marrow transplant, is a potentially curative treatment for some patients with leukaemia. This procedure replaces diseased bone marrow with healthy stem cells from a donor or, in some cases, from the patient themselves if the cells were collected when the disease was in remission. Before the transplant, patients receive high doses of chemotherapy or radiation to destroy all the cancer cells in their bone marrow. Then, healthy stem cells are infused into the bloodstream, where they travel to the bone marrow and begin producing new, healthy blood cells. This treatment is intensive and carries risks, so it’s typically reserved for patients whose leukaemia is difficult to control with other treatments or who have a high risk of relapse.^[10][14]

Treatment duration varies widely depending on the type of leukaemia and how well the patient responds. Acute leukaemia treatment typically lasts several months, with intensive phases followed by consolidation therapy. Patients with chronic leukaemia may take daily medicines for years or even indefinitely, with ongoing monitoring through regular blood tests and medical appointments.^[14][15]

Innovative Treatments Being Tested in Clinical Trials

Clinical trials are research studies where patients volunteer to test new treatments that aren’t yet widely available. These trials follow careful protocols to test whether new drugs or treatment approaches are safe and work better than existing options. Clinical trials are conducted in phases, with each phase designed to answer specific questions. Phase I trials test whether a new treatment is safe and determine the right dose. Phase II trials look at whether the treatment actually works against the cancer. Phase III trials compare the new treatment directly with standard treatments to see if it offers real advantages.^[3][4]

Immunotherapy is one of the most exciting areas of research in leukaemia treatment. These treatments harness the power of the patient’s own immune system to recognize and attack cancer cells. Several immunotherapy drugs have already been approved for leukaemia and are now part of standard treatment, while many more are being tested in trials. One type of immunotherapy uses monoclonal antibodies, which are proteins designed to attach to specific targets on leukaemia cells. Some antibodies work by marking cancer cells so the immune system can find and destroy them. Others carry toxic drugs directly to cancer cells, killing them while sparing healthy cells nearby.^[13]

Several monoclonal antibodies are now approved for specific types of leukaemia. Rituximab targets a protein called CD20 found on the surface of certain leukaemia cells and is approved for chronic lymphocytic leukaemia. Alemtuzumab targets CD52 and is used for some patients with chronic lymphocytic leukaemia. For acute lymphoblastic leukaemia, doctors may prescribe inotuzumab ozogamicin, an antibody-drug conjugate that delivers toxic chemicals directly to cancer cells bearing the CD22 protein. Another innovative antibody called blinatumomab is a bispecific antibody that connects cancer cells to immune cells, bringing them together so the immune system can attack the cancer.^[13]

Adoptive cell therapy, particularly CAR T-cell therapy, represents a revolutionary approach to treating leukaemia. In this treatment, doctors remove some of the patient’s own immune cells called T cells from their blood. In the laboratory, these T cells are genetically modified to produce special receptors called chimeric antigen receptors, or CARs, on their surface. These receptors enable the T cells to recognize and attach to specific proteins on leukaemia cells. The modified cells are then multiplied to create millions of copies and infused back into the patient’s bloodstream, where they hunt down and destroy cancer cells.^[13]

Several CAR T-cell therapies have been approved for acute lymphoblastic leukaemia. Brexucabtagene autoleucel and tisagenlecleucel are approved for patients whose disease hasn’t responded to other treatments or has come back after initial treatment. These therapies have shown remarkable results in some patients, with many achieving complete remission. However, CAR T-cell therapy can cause serious side effects, including cytokine release syndrome, a condition where the immune system becomes overactive and causes fever, low blood pressure, and breathing difficulties. Patients receiving CAR T-cell therapy need careful monitoring in specialized centres.^[13]

Researchers are developing new generations of CAR T-cell therapies that may work better and cause fewer side effects. Some trials are testing CAR T cells that target different proteins on leukaemia cells, while others are creating “universal” CAR T cells from healthy donors rather than from each individual patient. These off-the-shelf products could make the treatment more accessible and less expensive. Clinical trials of these next-generation CAR T therapies are taking place in major cancer centres across the United States, Europe, and other regions.^[12][13]

New targeted therapy drugs are constantly being developed and tested. These medicines work by blocking specific molecular pathways that leukaemia cells use to grow and survive. For example, some drugs called BCL-2 inhibitors work by triggering programmed cell death in cancer cells. Venetoclax is one such drug that has been approved for chronic lymphocytic leukaemia and some types of acute myeloid leukaemia. It’s often combined with other drugs to improve effectiveness. Clinical trials are testing whether venetoclax works for other types of leukaemia and whether different combinations might produce even better results.^[12]

FLT3 inhibitors are another class of targeted drugs being used and studied for acute myeloid leukaemia. About one-third of patients with this type of leukaemia have a mutation in a gene called FLT3, which helps cancer cells grow faster. Drugs like midostaurin and gilteritinib block the activity of the abnormal FLT3 protein, slowing down or stopping the growth of cancer cells. Clinical trials have shown that these drugs can improve survival when used alongside chemotherapy or when other treatments have failed. Researchers are testing new FLT3 inhibitors that might work better or have fewer side effects.^[12]

IDH inhibitors represent another innovative approach for acute myeloid leukaemia. Some patients have mutations in genes called IDH1 or IDH2, which cause abnormal cell development. Drugs like ivosidenib and enasidenib block these abnormal proteins and help cancer cells mature into normal blood cells. These targeted drugs are taken as pills and have shown promising results in clinical trials, particularly for older patients who might not tolerate intensive chemotherapy. Ongoing trials are exploring whether combining IDH inhibitors with other treatments might improve outcomes even further.^[12]

Bispecific antibodies are being developed that can simultaneously bind to cancer cells and immune cells, bringing them close together. Beyond blinatumomab, which is already approved, several new bispecific antibodies are in clinical trials for different types of leukaemia. These drugs are given as injections or infusions and work by helping the patient’s immune system recognize and attack leukaemia cells. Early trial results have been encouraging, showing that these antibodies can be effective even in patients whose disease has stopped responding to other treatments. Researchers are testing different dosing schedules and combinations to maximize effectiveness while minimizing side effects.^[12][13]

Epigenetic therapy is an emerging field that focuses on drugs affecting how genes are turned on or off in cancer cells. Unlike chemotherapy, which kills rapidly dividing cells, or targeted therapy, which blocks specific proteins, epigenetic drugs work by changing gene expression patterns. Drugs like azacitidine and decitabine are already used for certain blood cancers and are being tested in combination with other treatments for various types of leukaemia. These drugs may help make cancer cells more sensitive to other treatments or restore normal gene function. Clinical trials are investigating new epigenetic drugs and optimal combinations with immunotherapy or targeted therapy.^[12]

Clinical trials for leukaemia are conducted at major cancer centres and hospitals around the world. In the United States, institutions like MD Anderson Cancer Center, Memorial Sloan Kettering, and the National Cancer Institute run numerous leukaemia trials. European countries including the United Kingdom, Germany, and France have active research programs, as do centres in Australia, Japan, and Canada. To be eligible for a trial, patients typically need to meet specific criteria related to their age, type of leukaemia, previous treatments, and overall health. Doctors can help patients search for appropriate trials and determine whether participation might be beneficial.^[4][12]

Preliminary results from many clinical trials have been promising. Some trials report that significant percentages of patients achieve remission with new treatments, even when previous therapies have failed. Others show improvements in survival times or better quality of life with fewer side effects. However, it’s important to remember that not all experimental treatments succeed, and what works in early trials doesn’t always prove effective in larger studies. This is why continuing research and rigorous testing are so crucial.^[12][13]

Most Common Treatment Methods

• Chemotherapy
  • Intensive induction chemotherapy using combinations of drugs delivered through intravenous infusion
  • Consolidation chemotherapy to prevent disease relapse after achieving remission
  • Less intensive chemotherapy options for patients who cannot tolerate aggressive treatment
  • Oral chemotherapy tablets for chronic leukaemias
• Targeted Therapy
  • BCL-2 inhibitors like venetoclax for chronic lymphocytic leukaemia and acute myeloid leukaemia
  • FLT3 inhibitors such as midostaurin and gilteritinib for acute myeloid leukaemia with FLT3 mutations
  • IDH inhibitors including ivosidenib and enasidenib for acute myeloid leukaemia with IDH mutations
  • Tyrosine kinase inhibitors for chronic myeloid leukaemia
• Immunotherapy
  • Monoclonal antibodies like rituximab, alemtuzumab, and obinutuzumab targeting specific proteins on leukaemia cells
  • Antibody-drug conjugates such as inotuzumab ozogamicin and gemtuzumab ozogamicin
  • Bispecific antibodies like blinatumomab that connect cancer cells to immune cells
• Adoptive Cell Therapy
  • CAR T-cell therapy using genetically modified immune cells to attack leukaemia
  • Brexucabtagene autoleucel for acute lymphoblastic leukaemia
  • Tisagenlecleucel for pediatric and young adult acute lymphoblastic leukaemia
• Stem Cell Transplantation
  • Allogeneic transplant using donor stem cells to replace diseased bone marrow
  • Autologous transplant using the patient’s own previously collected stem cells
  • High-dose chemotherapy or radiation followed by stem cell infusion
• Radiation Therapy
  • Targeted radiation to areas where leukaemia cells have accumulated
  • Total body irradiation as preparation for stem cell transplant
  • Cranial radiation when leukaemia has spread to the nervous system
• Supportive Therapy
  • All-trans retinoic acid (ATRA) for acute promyelocytic leukaemia
  • Arsenic trioxide for relapsed acute promyelocytic leukaemia
  • Growth factors to stimulate blood cell production
  • Blood and platelet transfusions to manage low blood counts
  • Antibiotics to prevent and treat infections
• Watchful Waiting
  • Active monitoring with regular blood tests and check-ups
  • Delaying treatment until disease progression or symptoms develop
  • Often used for early-stage chronic lymphocytic leukaemia